glucagon has been researched along with Cardiomyopathies in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heitner, SB; Merkel, MJ; Schulman, PM; Young, AT | 1 |
| Chen, S; Grayburn, P; Orci, L; Ravazzola, M; Unger, RH; Wang, MY | 1 |
| Blanz, J; Eskelinen, EL; Guhde, G; Hartmann, D; Janssen, PM; Lüllmann-Rauch, R; Saftig, P; Suter, A; Tanaka, Y; von Figura, K | 1 |
| Grabensee, B; Grosse-Brockhoff, F | 1 |
| Torp, A | 1 |
| Cros, GH; McNeill, JH; Michel, A; Serrano, JJ | 1 |
| Amsterdam, EA; King, JF; Mason, DT; Massumi, RA; Salel, AF; Zelis, R | 1 |
| Border, JF; Childress, RH; Chip, JN; Williams, JF | 1 |
9 other study(ies) available for glucagon and Cardiomyopathies
| Article | Year |
|---|---|
Focused Echocardiography During Glucagon Administration to Diagnose Beta-Blocker-Induced Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Cardiomyopathies; Echocardiography; Glucagon; Hormones; Humans; Injections, Intravenous; Male | 2015 |
Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Calcium-Binding Proteins; Cardiomyopathies; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Glucagon; Insulin; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Mice; Mice, Transgenic; Obesity; Pancreas; Promoter Regions, Genetic; Receptors, Leptin; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transgenes | 2008 |
Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice.
Topics: Amino Acids; Animals; Antigens, CD; Autophagy; Body Weight; Cardiomyopathies; Cells, Cultured; Crosses, Genetic; Female; Gene Targeting; Glucagon; Humans; Liver; Lysosomal Membrane Proteins; Lysosomal Storage Diseases; Male; Membrane Glycoproteins; Mice; Muscles; Myocardial Contraction; Organ Size; Pancreas; Vacuoles | 2000 |
[Therapeutic modification of contractility under clinical conditions].
Topics: Adrenergic beta-Antagonists; Calcium; Cardiomyopathies; Catecholamines; Digitalis Glycosides; Glucagon; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Nitrites | 1976 |
Special investigations in COCM: biochemical analysis of cardiac biopsies.
Topics: Alcoholism; Cardiomyopathies; Cyclic AMP; Glucagon; Heart; Hemodynamics; Humans; Myocardium; Phospholipids; Triglycerides | 1978 |
Cardiac adenylate cyclase activity in streptozotocin-treated rats after 4 months of diabetes: impairment of epinephrine and glucagon stimulation.
Topics: Adenylyl Cyclases; Animals; Calcium; Cardiomyopathies; Cell Membrane; Diabetes Mellitus, Experimental; Epinephrine; Glucagon; Insulin; Male; Myocardium; Rats; Rats, Inbred Strains | 1985 |
Panel discussion: the treatment of congestive cardiomyopathy.
Topics: Cardiomegaly; Cardiomyopathies; Digitalis Glycosides; Glucagon; Humans; Rest; Steroids | 1972 |
Recent advances in therapy for refractory congestive heart failure.
Topics: Adrenal Cortex Hormones; Aminophylline; Cardiac Catheterization; Cardiomyopathies; Dextrothyroxine; Digitalis Glycosides; Diuretics; Dopamine; Ethacrynic Acid; Furosemide; Glucagon; Heart; Heart Diseases; Heart Failure; Humans; Isoproterenol; Mannitol; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial | 1973 |
Hemodynamic effects of glucagon in patients with heart disease.
Topics: Blood Glucose; Blood Pressure; Cardiac Catheterization; Cardiac Output; Cardiomyopathies; Glucagon; Heart Rate; Hemodynamics; Humans; Hypertension; Isoproterenol; Male; Potassium; Time Factors; Vascular Resistance | 1969 |